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GRAND ROUNDS
Ganciclovir Therapeutic Drug Monitoring: A Case Series
Anne-Grete Märtson, MSc,* Daan Touw, PhD,* Kevin Damman, MD,† Martijn Bakker, MD,‡
Annemieke Oude Lansink-Hartgring, MD,§ Tjip van der Werf, PhD,¶║ Marjolein Knoester, MD,**
and Jan-Willem C. Alffenaar, PhD*
Abstract: This article presents 3 cases of immunocompromised
patients for whom therapeutic drug monitoring of ganciclovir in
combination with cytomegalovirus viral load measurement was used
to guide treatment. The ﬁrst patient is diagnosed with thymoma A,
the second is a heart transplant recipient, and the third is an HIV-
positive patient. These patients were all diagnosed with cytomega-
lovirus and treated with ganciclovir. Our case studies illustrate how
therapeutic drug monitoring–guided dosing can be helpful in the
management of these complex cases.
Key Words: ganciclovir, TDM, immunocompromised patients
(Ther Drug Monit 2019;41:107–110)
CLINICIAN
Our patient is a 54-year-old man (90 kg) with type A
thymoma, who was admitted to the intensive care unit
because of respiratory failure and shock. Laboratory results
showed severe hypogammaglobulinemia and absence of
circulating B cells, and therefore, the diagnosis of Good
syndrome was considered, and intravenous immunoglobulin
was started.1,2 Based on chest imaging followed by broncho-
scopic bronchoalveolar lavage, Pneumocystis jirovecii pneu-
monia (PCP) and cytomegalovirus (CMV) disease were
diagnosed (CMV DNA viral load of 775,000 copies/mL in
whole blood). The patient was CMV IgG positive thus suf-
fering from a reactivation of CMV. As the patients’ status
deteriorated further, he was referred for extracorporeal mem-
brane oxygenation. He was on sulfamethoxazole and trimeth-
oprim (960 mg once daily) and ganciclovir [2 mg/kg once
daily, intravenous (IV)] as well as continuous venovenous
hemoﬁltration (CVVH, 50 mL/min).
TDM CONSULTANT
For CMV treatment, the standard dosing of ganciclovir
is 900 mg every 12 hours for oral valganciclovir and 5 mg/kg
every 12 hours for IV ganciclovir.3 In case of renal impair-
ment and dialysis, dosages should be adjusted according to
renal function to avoid serious side effects such as neutrope-
nia and myelosuppression.4–7 Ganciclovir has a narrow ther-
apeutic window, and higher concentrations have been
connected to toxicity.8 Besides side effects, antiviral drug
resistance may impact CMV treatment. Resistance to ganci-
clovir is caused by mutations in the genes UL97 kinase and
UL54 polymerase.9 The risk for acquired resistance is
increased in patients with high viral loads, that is,
.100.000 copies/mL of blood.10 Adequate CMV treatment
is of great importance, and low ganciclovir serum concentra-
tions need to be avoided.10 To assure adequate ganciclovir
drug exposure, therapeutic drug monitoring (TDM) is an
easy-to-use tool to assess ganciclovir serum concentrations
and to guide dosage adjustments.11 I suggest you start the
TDM of ganciclovir for this patient. We can use a validated
liquid chromatography–tandem mass spectrometry method.
We have deﬁned a ganciclovir target plasma trough concen-
tration of 1–2 mg/L for CMV prophylaxis and 2–4 mg/L for
CMV treatment. These are based on the inhibitory concentra-
tion of CMV (IC50) and pharmacokinetic parameters derived
from available studies.6–8,12,13
CLINICIAN
I agree, to reduce the risks of ganciclovir treatment and
to guide therapy using TDM would be a good idea. The viral
load is now 283,000 copies/mL in plasma. The ﬁrst measured
trough concentration at steady state is 1.3 mg/L, and this is
the 13th day of treatment. I think we should increase the dose.
TDM CONSULTANT
I agree, I think the dose should be increased to 1.7 mg/
kg (intravenous) twice daily. We used a population pharma-
cokinetic model for ganciclovir dose estimation to which the
individual patient data were ﬁtted using Bayesian ﬁtting. The
model included following initial population pharmacokinetic
parameters: volume of distribution (0.74 6 0.15 L/kg), elim-
ination rate constant (0.023 6 0.1 h21), bioavailability (0.66
0.15), absorption rate constant (0.895 6 0.464 h21), lag time
(0.825 6 1.54 hours), and renal elimination constant [h21/
(mL/min/1.73 m2)].
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CLINICIAN
This dose has resulted in a trough concentration of 2.2
mg/L.
On day 16, the viral load is still high (127,000 copies/
mL in serum), and his condition has not improved. We
suspect resistance to ganciclovir. This, however, was not
conﬁrmed by Sanger sequencing of UL54 and UL97, so we
continued with ganciclovir while patient is still on CVVH.
We have kept the patient on the same dose, and on day 27, we
saw a reduction in viral load in serum to 1610 copies/mL.
Now on day 29, however, we have obtained a trough
concentration of 6.6 mg/L, what should our next step be?
TDM CONSULTANT
I suggest you continue with the 1.7 mg/kg once daily
dose. The total of 6.6 mg/L is the concentration where we can
see side effects and you have been having positive responses
to the higher dose.
CLINICIAN
We reduced the dose as you suggested; however, today,
on day 48, we see an increase in viral load and a measurement
of 2280 copies/mL in whole blood. In the meantime,
ganciclovir concentration has dropped to 0.4 mg/L. Do you
have a suggestion for dosage change?
TDM CONSULTANT
I suggest you increase the dose back to 1.7 mg/kg twice
daily.
CLINICIAN
We did increase the dose after your last suggestion;
however, it is day 52, and ganciclovir concentrations have
remained on the lower side.
TDM CONSULTANT
I suggest you increase the dose to 2.7 mg/kg twice
daily, knowing that the patient is also still on CVVH.
CLINICIAN
We increased the dose, and ganciclovir trough concen-
trations have subsequently increased to 3.9 mg/L, and the
patient remains on CVVH. It is day 62, and the viral load has
dropped to 900 copies/mL (whole blood). We have obtained 2
consecutive negative viral load measurements (,100 copies/
mL) on days 80 and 85. The patient is continued on valgan-
ciclovir tablet 900 mg twice daily.
I have another patient admitted with CMV. He is a 54-
year-old heart transplant recipient (transplanted 6 months
earlier; donor CMV IgG positive and recipient CMV IgG
negative). He was admitted to the hospital with shortness of
breath, nausea, and diarrhea that had lasted for 4 days. CMV
DNA in whole blood was 120,000 copies/mL. Primary CMV
infection has been diagnosed, and treatment is started with IV
ganciclovir 2.6 mg/kg once a day [while the estimated
glomerular ﬁltration rate (eGFR) was 24 mL/min/1.73 m2].
Do you think we should also start TDM of ganciclovir for this
patient?
TDM CONSULTANT
This would beneﬁt the patient especially, as he has
severe renal failure. Ganciclovir is mainly eliminated through
the kidney with glomerular and tubular secretion, and it has
been described that more than 80% of unchanged ganciclovir
is found in urine.8 Thus, the clearance of ganciclovir during
renal impairment and renal replacement therapy is changed,
and in that case, the dosages should be adjusted accordingly,
and TDM may be indicated.6
CLINICIAN
On day 9, ganciclovir trough concentration was 1.2 mg/
L (eGFR 32 mL/min/1.73 m2), and the viral load had dropped
to 27.800 copies/mL (in whole blood). However, the viral
load has shown no further decline for the next 3 days (viral
load 32,000 copies/mL in whole blood). We suspected that
there is resistance to ganciclovir, and we decided to start with
foscarnet treatment. After initiation of foscarnet treatment, an
adverse drug reaction was noticed with vomiting, nausea, and
exanthema, and therapy with foscarnet has now been stopped.
The treatment with foscarnet lasted for 3 days. In the mean-
time, resistance against ganciclovir was not conﬁrmed by
Sanger sequencing of UL54 and UL97. We have decided to
continue with ganciclovir.
TDM CONSULTANT
I suggest increasing the dose to 1.5 mg/kg three times
daily.
CLINICIAN
We followed your suggestion, and the measured trough
concentration was 3.7 mg/L, while the patient still suffered
from severe kidney failure (eGFR 23 mL/min/1.73 m2). By
day 22, the viral load has dropped to 415 copies/mL (in whole
blood). We discharged the patient on day 32 with oral val-
ganciclovir 450 mg twice daily (ganciclovir trough 3.1 mg/L,
eGFR 31 mL/min/1.73 m2). Further TDM was performed
during outpatient follow-up (day 36: 3 mg/L, day 39: 2.5
mg/L). On the 40th and 43rd day of treatment, we obtained
2 consecutive negative viral load measurements (,100
copies/mL in whole blood). This patient’s dosing is presented
in Figure 1.
CLINICIAN
We have a 43-year-old man, who was referred to us
with newly diagnosed HIV infection. He has lost approxi-
mately 7 kg in the past 6 months and felt progressive
shortness of breath with a cough. The patient has been tested
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for hepatitis B and C in serum (serology), and RT-PCR was
performed on bronchoalveolar lavage ﬂuid for CMV, PCP,
herpes simplex virus types 1 and 2, and Toxoplasma gondii.
PCP has been conﬁrmed with polymerase chain reaction and
Giemsa staining, and treatment has been started with sulfa-
methoxazole, trimethoprim (1920 mg three times daily), and
prednisolone (40 mg twice daily). Herpes simplex virus type
1 (DNA) has also been found, with a cycle threshold (Ct-
value) of 30. HIV is being treated with darunavir/cobicistat
and emtricitabine/tenofovir. Now, 13 days after presentation,
CMV viremia has been detected (15.900 copies/mL in whole
blood, IgG positive). In addition, esophagitis grade D has
been diagnosed for which he is being treated with omeprazole
and ﬂuconazole. We have started ganciclovir with a dose of 4
mg/kg twice daily (eGFR 115 mL/min/1.73 m2).
TDM CONSULTANT
This dose seems low, as his kidney function is normal,
and I suggest increasing the dose and starting the TDM of
ganciclovir.
CLINICIAN
The ﬁrst 2 trough levels are on the low side (0.4 and 1.5
mg/L on days 2 and 4); we decided to increase the dose to 4
mg/kg four times daily. This resulted in a trough concentra-
tion of 1.9 mg/L on day 5 (eGFR 111 mL/min/1.73 m2). By
day 8, the viral loads decreased to 241 copies/mL (in whole
blood). We switched intravenous treatment to oral valganci-
clovir treatment on day 8 (900 mg once daily), and the patient
was discharged from the hospital. We obtained 2 consecutive
negative viral load measurements (,100 copies/mL) on days
16 and 21.
We presented 3 patients illustrating how the TDM of
ganciclovir helped in their management. For these patients,
the dosage changes are performed in a somewhat different
pattern. This is because we do not have extensive experience
with the TDM of ganciclovir, and there is no established
dosing algorithm. However, the use of the population
pharmacokinetic model in combination with Bayesian ﬁtting
of individual data allows for an individual TDM approach.
The third patient had a low starting dose of 4 mg/kg
twice daily; in retrospect, we consider this dosing inadequate
as reﬂected by the measured concentrations. However, for this
patient, starting off with 5 mg/kg twice daily most likely
would have resulted in low concentrations as well. Without
TDM, these 3 patients would have received ganciclovir doses
that were too low, which could have led to unnecessary
switch of treatment (1 case) or to acquired resistance to
ganciclovir.10
Although the diagnosis and management of CMV has
improved in recent years, it is still considered a common
complication for immunocompromised patients, especially
for solid organ and stem cell transplant recipients.3,14 The
prophylaxis and preemptive therapy approaches have shown
to be beneﬁcial in avoiding severe infection. TDM for ganci-
clovir is useful; however, the necessity of routine TDM for
ganciclovir has been a subject of debate.8,15,16 There are cur-
rently insufﬁcient data for conﬁrming the need for routine
TDM of ganciclovir; only case studies have suggested its
wider use.17–19
The published case studies are unique and differ from
the 3 cases we described here. Peredo et al17 investigated
mainly the feasibility of using brain extracellular ﬂuid (using
microdialysis) to measure ganciclovir concentrations and con-
cluded that concentrations in brain tissue are comparable with
those from serum. On the other hand, Stockmann et al18 only
FIGURE 1. Bayesian-simulated ganciclovir serum concentrations during treatment and CMV DNA viral load in blood of the
second presented patient. The shaded area presents the time patient was on foscarnet treatment. bid, twice daily; po, orally; qd,
once daily; tid, three times daily.
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brieﬂy described a pediatric case where they used the area
under the concentration–time curve over 24 h (AUC24) values
to determine exposure to ganciclovir in a patient with con-
ﬁrmed ganciclovir resistance. Another case study by Nunez-
Nunez described how continuous renal replacement therapy
affects the elimination of ganciclovir.19 Applicability and use
in patient care was not discussed in detail in these cases.
Moreover, any consensus about an appropriate concentration
for ganciclovir was not reached. With our 3 case studies, we
showed how TDM may be of help to guide treatment in
hospitalized patients.
Furthermore, another important reason why TDM
should be performed is the necessity for dosage alterations
in kidney dysfunction, as it is mainly excreted trough the
kidneys.20 Also, for CMV treatment, higher doses and often
intravenous administration of ganciclovir are used, which are
adjusted to body weight. This can increase the variability in
drug concentrations because both exposure and clearance can
change.7,8,19 These patients can also be critically ill, thus
require continuous hemoﬁltration, which makes dose estima-
tion without TDM difﬁcult.7 These criteria suggest that TDM
can be a useful tool in monitoring ganciclovir treatment.
Our case studies illustrate how TDM-guided dosing can
be helpful in the management of these complex cases.
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